Biote to Present at 35th Annual Roth Conference
2023年3月2日 - 10:00PM
ビジネスワイヤ(英語)
biote Corp. (Nasdaq: BTMD) (“Biote” or the
“Company”), a leading innovator in preventive health care through
the delivery of personalized hormone therapy, today announced its
participation in the 35th Annual Roth Conference, to be held March
12-14, 2023, in Dana Point, CA.
Biote’s Chief Executive Officer, Terry Weber, and Chief
Financial Officer, Samar Kamdar, will present at the conference on
March 14, 2023, at 10:00 a.m. local time. Ms. Weber, Mr. Kamdar,
and Marc Beer, Biote’s Chairman, will also participate in investor
meetings throughout the conference.
About Biote
Biote is transforming healthy aging through innovative,
personalized hormone optimization therapies delivered by
Biote-certified medical providers. Biote trains practitioners how
to identify and treat early indicators of hormone-related aging
conditions, an underserved $7 billion global market, providing
affordable symptom relief for patients and driving clinic success
for practitioners.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Some of the forward-looking statements can be identified
by the use of forward-looking words. Statements that are not
historical in nature, including the words “may,” “can,” “should,”
“will,” “estimate,” “plan,” “project,” “forecast,” “intend,”
“expect,” “hope,” “anticipate,” “believe,” “seek,” “target,”
“continue,” “could,” “might,” “ongoing,” “potential,” “predict,”
“would” and other similar expressions, are intended to identify
forward-looking statements. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual results or developments to differ materially from
those expressed or implied by such forward-looking statements. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the “Risk Factors” section of
Biote’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2022 and other documents filed by Biote from time to
time with the Securities and Exchange Commission. These filings
identify and address other important risks and uncertainties that
could cause actual events and results to differ materially from
those contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Biote assumes no obligation and does not intend to update or
revise these forward-looking statements, whether as a result of new
information, future events, or otherwise. Biote does not give any
assurance that it will achieve its expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230302005291/en/
Investor Relations: Eric Prouty AdvisIRy Partners
eric.prouty@advisiry.com Media: Press@biote.com
Biote (NASDAQ:BTMD)
過去 株価チャート
から 2 2025 まで 3 2025
Biote (NASDAQ:BTMD)
過去 株価チャート
から 3 2024 まで 3 2025